Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

Annals of neurology·2022
Same author

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Multiple sclerosis and related disorders·2016
Same author

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.

Expert review of neurotherapeutics·2015
Same author

Progressive multiple sclerosis: characteristics and management.

Neurologic clinics·2011
Same author

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Therapeutic advances in neurological disorders·2010
Same author

B cells as a target of immune modulation.

Annals of Indian Academy of Neurology·2010
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Primary progressive multiple sclerosis.

Kathleen Hawker

    Continuum (Minneapolis, Minn.)
    |July 20, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Primary progressive multiple sclerosis (PPMS) presents a diagnostic challenge due to its insidious progression. Understanding PPMS pathogenesis offers insights into multiple sclerosis progression overall.

    More Related Videos

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    Related Experiment Videos

    Last Updated: May 20, 2026

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    Area of Science:

    • Neurology
    • Neuroimmunology
    • Clinical Neuroscience

    Background:

    • Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of all multiple sclerosis cases.
    • PPMS is characterized by insidious disease progression from onset, distinguishing it from relapsing-remitting MS.
    • Diagnosis of PPMS can be challenging, frequently leading to misdiagnosis and delayed treatment initiation.

    Purpose of the Study:

    • To highlight the diagnostic difficulties associated with primary progressive multiple sclerosis.
    • To underscore the importance of understanding the pathogenesis of PPMS.
    • To elucidate how insights into PPMS can inform the broader understanding of multiple sclerosis progression.

    Main Methods:

    • Review of clinical characteristics differentiating PPMS from other MS forms.
    • Analysis of diagnostic challenges and common pitfalls.
    • Examination of current understanding of PPMS pathogenesis.

    Main Results:

    • PPMS exhibits a distinct, gradual progression pattern from disease onset.
    • Diagnostic delays and misdiagnoses are prevalent in PPMS cases.
    • Pathogenic insights into PPMS are crucial for understanding disease progression across all multiple sclerosis phenotypes.

    Conclusions:

    • Despite the absence of effective treatments, understanding PPMS pathogenesis is vital.
    • Insights gained from studying PPMS contribute to a comprehensive understanding of multiple sclerosis.
    • Accurate and timely diagnosis of PPMS remains a significant clinical challenge.